Paris, May 31, 2021 (GLOBE NEWSWIRE) – (Graz and Paris – June 1, 2021) – Curium has successfully completed the acquisition of the Austrian radiopharmacy company IASON, thus expanding its footprint in Europe for its broad portfolio of lifesaving diagnostics solutions. This is the second acquisition of a positron emission tomography (PET) radiopharmaceutical business by Curium this year following the acquisition of M2i, a leading Irish PET player, earlier this year. . As part of the transaction, certain non-core businesses, including a real estate portfolio, were ceded to a group of contractors.
IASON operates two GMP manufacturing sites in Austria, one in Linz and one in Klagenfurt, and has been supplying critical radiopharmaceuticals to customers in Austria and Central Europe since 1994. The company employs approximately 65 people and offers a wide range of diagnostic tracers PET.
“We look forward to integrating IASON into our network of 27 PET sites across Europe,” says Benoit Woessmer, CEO of PET EUROPE at Curium. “This acquisition complements our current geographic footprint and allows us to offer our broad product portfolio and future pipeline of innovative agents to our customers and patients in Austria and Central Europe.”
“Being part of a global innovation-driven nuclear medicine platform like Curium would be a tremendous opportunity for IASON and its team of talented employees to further their careers in this exciting field,” commented Mag. Christoph Artner, founder of IASON. “I wish them all the best for the journey ahead.”
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceuticals to help patients around the world. Our proven heritage combined with a pioneering approach is the hallmark of innovation, excellence and unmatched service.
With manufacturing facilities in Europe and the United States, Curium provides therapeutic SPECT, PET and radiopharmaceutical solutions for life-threatening diseases to more than 14 million patients each year. The name “Curium” pays homage to the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes nuclear medicine.
To learn more, visit www.curiumpharma.com. For more information on this press release, please contact Sabine Chestier, media contact for Curium: [email protected]
IASON, founded in 1994, is an independent Austrian company IASON is a leading specialist in Europe for the development, production and distribution of radiopharmaceuticals for positron emission tomography (PET). With its culture of innovation and highly skilled employees, IASON helps thousands of cancer patients live longer and better lives.
The company operates two state-of-the-art PET radiopharmaceutical manufacturing facilities in Austria (Linz and Klagenfurt) and supplies specialized PET products to private and public hospitals in Austria and Central Europe.